Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951055 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL588656 | 0.86 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL588544 | 0.86 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL5543652 | 0.86 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Hydrochloric Acid SCHEMBL588157 | 0.85 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Hydrochloric Acid SCHEMBL588156 | 0.85 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2952322 | 0.85 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2952327 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2943412 | 0.83 | SLC6A4 (0.75) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL2950159 | 0.81 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1441728-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| WO-2003037338-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | SLC6A4 2317/4885SLC6A3 1625/4885SLC6A2 2016/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | SLC6A4 3719/4885SLC6A3 4243/4885SLC6A2 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.